Helix Biopharma Corp.
HBPCF
$1.73
$1.13188.97%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 387.00K | 345.70K | 455.20K | 312.40K | 199.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 668.80K | 697.30K | 1.09M | 909.20K | 1.17M |
| Operating Income | -668.80K | -697.30K | -1.09M | -909.20K | -1.17M |
| Income Before Tax | -726.40K | -691.50K | -1.09M | -967.60K | -978.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -726.40K | -691.50K | -1.09M | -967.60K | -978.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -726.40K | -691.50K | -1.09M | -967.60K | -978.50K |
| EBIT | -668.80K | -697.30K | -1.09M | -909.20K | -1.17M |
| EBITDA | -667.30K | -696.60K | -1.09M | -907.80K | -1.16M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 75.87M | 70.90M | 53.04M | 50.07M | 49.02M |
| Average Diluted Shares Outstanding | 75.87M | 70.90M | 53.04M | 50.07M | 49.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |